Phathom Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHAT research report →
About the company
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada.
- CEO
- Steven L. Basta
- IPO
- 2019
- Employees
- 427
- HQ
- Florham Park, NJ, US
Price Chart
- Market Cap
- $893.27M
- P/E
- -5.28
- P/S
- 4.36
- P/B
- -2.73
- EV/EBITDA
- -9.67
- Div Yield
- 0.00%
- Gross Margin
- 84.93%
- Op Margin
- -47.15%
- Net Margin
- -76.77%
- ROE
- 39.24%
- ROIC
- -53.45%
- Revenue
- $175.11M · 216.93%
- Net Income
- $-221,247,000 · 33.82%
- EPS
- $-3.03 · 42.72%
- Op Income
- $-159,986,000
- FCF YoY
- 37.52%
- 52W High
- $18.31
- 52W Low
- $7.61
- 50D MA
- $11.13
- 200D MA
- $12.70
- Beta
- 0.49
- Avg Volume
- 1.19M
Get TickerSpark's AI analysis on PHAT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 22, 26 | Parikh Asit | other | 28,000 |
| May 22, 26 | Parikh Asit | other | 28,000 |
| May 20, 26 | Parikh Asit | other | 17,500 |
| May 19, 26 | Parikh Asit | other | 24,122 |
| May 20, 26 | Parikh Asit | sell | 17,500 |
| May 19, 26 | Topper James N | other | 24,122 |
| May 19, 26 | Stenhouse Mark | other | 24,122 |
| May 19, 26 | FIELDS HEIDI | other | 24,122 |
| May 19, 26 | COLA MICHAEL F | other | 24,122 |
| May 19, 26 | KARBE FRANK | other | 24,122 |
Our PHAT coverage
Recent articles, reports, and earnings notes.
No research on PHAT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHAT report →Similar companies
Peers in the same neighborhood.